Recent biotech advances have led to a proliferation of advanced therapeutic products for treating diseases. Regulatory agencies face the challenge of setting standards to ensure public health protection and the quality of these therapies, while not hindering their development. Developers must navigate regulatory frameworks for clinical trials and overcome challenges in classifying investigational medicinal products.
"*" indicates required fields